Recent Updates
Recently added Catalysts

PF-08161842

Phase 1

Alzheimer Disease | Small molecule | Neurology |Pfizer, Inc.|Trials Updated: Oct 30, 2026

PF-08161842 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Oct 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindCONTROLLED
Total Trials1
Total Enrollment98

FDA Designations

No designations recorded

PF-08161842 clinical trials

PF-08161842 · 1 trial · 1 indication

Phase 1 1
NCT07897708A Study to Learn How Different Amounts of the Study Medicine Called PF-08161842 Are Tolerated and Act in the Body in Healthy and Older AdultsAlzheimer Disease
NOT YET_RECRUITING98 Analytics
PHASE1NOT YET_RECRUITING
A Study to Learn How Different Amounts of the Study Medicine Called PF-08161842 Are Tolerated and Act in the Body in Healthy and Older Adults
Alzheimer Disease
NCT0789770898
Unlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants With Treatment Emergent Adverse Events (TEAEs)
From first dose through approximately 28 to 35 days after the last dose
Number of Participants With Serious Adverse Events (SAEs)
From first dose through approximately 28 to 35 days after the last dose
Number of Participants With Clinically Significant Laboratory Abnormalities
From first dose through approximately 28 to 35 days after the last dose
Number of Participants With Clinically Significant Vital Signs Abnormalities
From first dose through approximately 28 to 35 days after the last dose
Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings
From first dose through approximately 28 to 35 days after the last dose
Number of Participants With Clinically Significant Columbia-Suicidality Severity Rating Scale (C-SSRS)
From first dose through approximately 28 to 35 days after the last dose

Secondary Endpoints

Area Under the Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast)
Part A only: Up to Day 5
Area Under the Curve From Time Zero to end of Dosing Interval (AUCtau)
Part B only: Up to Day 17
Maximum Observed Plasma Concentration (Cmax)
Part A: Up to Day 5 Part B: Up to Day 17
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeBASIC_SCIENCE

Treatment Arms

ArmTypeDescription
Part A: Cohorts 1-6 and 7 (optional)EXPERIMENTALParticipants will receive PF-08161842 or matching placebo as a single dose on Day 1.
Part B: Cohort 8-12 and 13 (Optional)EXPERIMENTALParticipants will receive doses of PF-08161842 or matching placebo from Day 1 through Day 14.

Interventions

NameTypeDescription
PF-08161842DRUGOral tablet (Parts A and B).
Placebo for PF-08161842DRUGMatching placebo tablet (Parts A and B).
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 85 Years
SexALL
Healthy VolunteersYes

Inclusion criteria: 1. Healthy adults, ages 18 to 64 years and healthy older adults, ages 65 to 85 years. 2. Body mass index (BMI) of 16-32 kg/m2; and a total body weight \>50kg (110 lb.). Exclusion criteria: 1. Evidence or history of clinically significant medical conditions. 2. Participation in...

Unlock Eligibility Criteria

Competitive Landscape -Alzheimer's Disease 105 trials (matched to "Alzheimer Disease")

Top 20 of 30 competitors

CompanyTickerTrialsLead PhaseDrugs
Bristol-Myers Squibb CompanyBMY11PHASE3Xanomeline and trospium chloride, KarX-EC, Xanomeline/Trospium Chloride, BMS-986446, X/T+ X-EC
Eli Lilly and CompanyLLY18PHASE3Donanemab, Remternetug, LY4560736, LY3954068, Flortaucipir F18
Biogen Inc.BIIB2PHASE3Lecanemab
Annovis Bio IncANVS1PHASE3Buntanetap
ACADIA Pharmaceuticals Inc.ACAD2PHASE3ACP-204
Hoffmann-La RocheRHHBY9PHASE3Trontinemab, RO7269162, RO7568282, RO7812653
Novartis AG Sponsored ADRNVS2PHASE2VHB937, NIO752
Johnson & JohnsonJNJ1PHASE2JNJ-64042056
Merck & Co., Inc.MRK1PHASE2MK-2214
Lantheus Holdings IncLNTH2PHASE3PI2620
Acumen Pharmaceuticals, Inc.ABOS1PHASE2sabirnetug
Cognition Therapeutics, Inc.CGTX1PHASE2CT1812
Aclaris Therapeutics, Inc.ACRS1PHASE2ATI-045
IGC Pharma, Inc.IGC1PHASE2IGC-AD1
GSK plc Sponsored ADRGSK1PHASE2GSK4527226
Alnylam Pharmaceuticals, IncALNY2PHASE1ALN-5288, ALN-APP
Denali Therapeutics Inc.DNLI2PHASE1DNL628, DNL921
Arrowhead Pharmaceuticals, Inc.ARWR1PHASE1ARO-MAPT
Sanofi SA Sponsored ADRSNY1PHASE2SAR448851
Neurocrine Biosciences, Inc.NBIX1PHASE2NBI-1117567
Unlock Competitive Intelligence

Recent Changes (Last 90 Days)

LOWOct 30, 2026NCT07897708lastUpdatePostDate: changed
LOWOct 30, 2026NCT07897708lastUpdatePostDate: changed
LOWOct 27, 2026NCT07897708NEW_TRIAL: changed
LOWOct 27, 2026NCT07897708NEW_TRIAL: changed

Explore more on BiopharmaWatch

Pfizer, Inc. (PFE)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with PCompanies A to ZEvery biotech and pharma company we track